New Two-Pronged attack on tough cancers
NCT ID NCT07446049
Summary
This trial is testing a new combination treatment for people with advanced solid tumors that have a specific genetic feature called PTEN loss or low expression. About 180 participants will take a pill called CVL237 along with an immunotherapy injection called serplulimab. The main goals are to find the safest dose and see if the combination can slow or stop cancer growth in patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.